EGM
RPRX icon

Encore Global Management’s Royalty Pharma RPRX Stock Holding History

Encore Global Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$112K Buy
+2,000
New +$104K 0.11% 50

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Encore Global Management's RPRX Position: Q2 2026 in Review

Encore Global Management opened a new position in Royalty Pharma (RPRX) in Q2 2026: 2,000 shares worth $112K. The stake represents 0.11% of the portfolio and ranks #50 among its holdings.

641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Encore Global Management held 2,000 shares of Royalty Pharma worth $112K as of Q2 2026.
  • Royalty Pharma was a new Encore Global Management position in Q2 2026.
  • Royalty Pharma made up 0.11% of Encore Global Management's portfolio in Q2 2026, its #50 holding.
  • 641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Encore Global Management's 13F filing for Q2 2026, filed 11 Aug 2026.